NSE filing, NSE: VENUSREM. Summary written from the filing by ALFA Finder's alert engine.
Venus Remedies Ltd: key numbers
- Share price
- ₹1,303.60
- Market cap
- ₹1,743 Cr
- Revenue (annual)
- ₹769.6 Cr
- Net profit (annual)
- ₹102.8 Cr
- P/E (TTM)
- 14.3×Sector 46.1×
- Promoter holding
- 41.76%+0.00% QoQ
- FII holding
- 3.14%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Venus Remedies Ltd
All →Venus Remedies Q2 FY27 Results: Net Profit ₹25.6 Cr, Up 27.4% YoY
Venus Remedies Ltd reported revenue from operations of ₹218.8 Cr (+13.5% YoY) and net profit of ₹25.6 Cr (+27.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹25.6 Cr · +27.4% YoY
Venus Remedies Regulatory Approval
Venus Remedies Limited secured five marketing authorizations for drugs including Vancomycin and Meropenem across Kazakhstan, Peru, Kuwait, and Argentina. These regulatory approvals expand its global pharmaceutical portfolio.
Venus Remedies Board Meeting Date
Venus Remedies will hold a board meeting on 26th October 2026 to consider and approve its unaudited standalone and consolidated financial results for the September quarter.
Venus Remedies Other Announcement
Venus Remedies Ltd has submitted its quarterly shareholding pattern for the period ended September 30, 2026, as required by SEBI regulations.
Venus Remedies Other Announcement
Venus Remedies Limited has announced a change in its Corporate Identification Number (CIN) following the alteration of its Memorandum of Association.
Venus Remedies Other Announcement
Venus Remedies Limited has informed the exchanges about its social media posts regarding a special window for the re-lodgement of physical share transfer requests.
Other management change announcements
All →CARE Ratings Management Change
CARE Ratings Limited appointed Mr. Jatindar Pal Singh Bajaj as a Non-Executive Non-Independent Director, effective October 29, 2026.
Alldigi Tech Management Change
Alldigi Tech appointed Alok Kumar Chaubey as Vice President - Sales, effective 29 October 2026. He brings over 15 years of HR Tech SaaS experience.
Indegene Management Change
Indegene's Company Secretary and Compliance Officer Srishti Ramesh Kaushik resigned, effective 02-Dec-2026. The resignation cites future career advancement.
EPACK Durables Management Change
EPACK Durable's CFO, Rajesh Kumar Mittal, resigned citing personal reasons, effective October 31, 2026. The resignation was disclosed alongside board meeting outcomes held October 29, 2026.
Qualitek Labs Management Change
Qualitek Labs' Independent Director Ajay Agarwal resigned effective October 29, 2026, citing personal reasons. He was not on any board committee, so no reconstitution is required.
Ambani Orgochem Management Change
Ambani Orgochem announced the resignation of non-executive non-independent director Bhavin Patel, effective 29 October 2026. The resignation was attributed to professional priorities and commitments.